<DOC>
	<DOCNO>NCT02065622</DOCNO>
	<brief_summary>To evaluate safety efficacy two dosing regimen achieve clinical remission subject moderately severely active Ulcerative Colitis .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Two Drug Regimens Subjects With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Ulcerative Colitis ( UC ) least 90 day , confirm endoscopy Screening period . Active UC Mayo Score 6 12 point endoscopy subscore 2 3 despite concurrent prior treatment full adequate course , opinion Investigator , oral corticosteroid immunosuppressant . Subject Crohn 's disease ( CD ) indeterminate colitis ( IC ) . Current diagnosis fulminant colitis and/or toxic megacolon . Subjects disease limited rectum ( ulcerative proctitis ) screen endoscopy . Chronic recur infection active Tuberculosis ( TB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>